• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Astellas Enters into Definitive Agreement to Acquire Iveric Bio

    4/30/23 7:00:00 PM ET
    $ISEE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ISEE alert in real time by email

    -Companies to Create World-Class Ophthalmology Entity-

    -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023-

    -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"-

    -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion-

    TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion (the "Acquisition"). In the Acquisition, Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. The total equity value of Iveric Bio in the Acquisition assumes that there are approximately 148.2 million outstanding shares of Iveric Bio common stock on a fully diluted basis. The purchase price represents a premium of 64% to Iveric Bio's unaffected closing share price of US$24.33 on March 31, 2023, and a premium of 75% to Iveric Bio's 30 trading day volume weighted average price as of March 31, 2023. The Boards of Directors of both companies have unanimously approved the transaction.

    Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.)

    "We are pleased to reach an agreement with Iveric Bio, a company with exceptional expertise in the R&D of innovative therapeutics in the ophthalmology field." said Naoki Okamura, President and CEO, Astellas. "Iveric Bio has promising programs including Avacincaptad Pegol ("ACP"), an important program for Geographic Atrophy ("GA") secondary to Age-Related Macular Degeneration ("AMD"), and capabilities across the entire value chain in the ophthalmology field. We believe that this acquisition will enable us to deliver greater VALUE to patients with ocular diseases at high risk of blindness."

    "This transaction with Astellas, a highly respected pharmaceutical company, demonstrates the significant value that we have built for our stockholders and recognizes the tremendous work by our dedicated team at Iveric Bio," said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. "The opportunity to create a world-class  entity with the ophthalmology  expertise and capabilities of Iveric Bio and the global reach and resources of Astellas is unique and has the potential to benefit patients worldwide suffering from blinding retinal diseases, including GA," said Pravin U. Dugel, MD, President of Iveric Bio.

    1.  Strategic Objectives of the Acquisition

    Astellas aims to become a cutting-edge, VALUE-driven life science innovator to realize its VISION to be "on the forefront of healthcare change to turn innovative science into VALUE for patients."Through Astellas' R&D strategy, Focus Area Approach, it is working to create innovative drugs for diseases with high unmet medical need by identifying unique combinations of biology and therapeutic modality / technology from multiple perspectives. Currently, Astellas has identified five Primary Focuses, including "Blindness & Regeneration", and is prioritizing investment resources in these areas. As such, this transaction is a key step in building Astellas' product portfolio in this important area.

    Iveric Bio focuses on the discovery and development of novel treatments in the field of ophthalmology. The company announced in February 2023 that the U.S. Food and Drug Administration ("FDA") accepted for filing a New Drug Application ("NDA") for ACP for the treatment of GA secondary to AMD. The NDA has been granted priority review with a Prescription Drug User Fee Act ("PDUFA") goal date of August 19, 2023.

    ACP, a complement C5 inhibitor, is an investigational drug for GA secondary to AMD and has significant potential to deliver value to a large and underserved patient base. ACP met its primary efficacy endpoint (reduction of the rate of GA progression) with statistical significance across two pivotal clinical trials, (GATHER Clinical Trials)  and has received breakthrough therapy designation*1 from the FDA for this indication.

    Astellas expects that the acquisition of Iveric Bio will not only contribute to Astellas' FY2025 revenue targets set in its Corporate Strategic Plan 2021, but also, that ACP in conjunction with fezolinetant and PADCEV, is anticipated to be a revenue-generating pillar to help compensate for the decline in sales of XTANDI due to anticipated patent expiration later this decade.

    In addition, the acquisition of Iveric Bio will provide a foundation of ophthalmology focused capabilities, including a multi-faceted commercial team, expansive network of experts in the ophthalmology field, established relationships with medical institutions, and the infrastructure and experience to drive our combined ophthalmology business going forward. Furthermore, through acquired capabilities, Astellas will accelerate pre-clinical and clinical development and commercialization activities to positively contribute to the goals of Primary Focus, "Blindness & Regeneration."

    Funds for the acquisition consist of newly procured funds from bank loans and issuing of commercial paper totaling approximately 800 billion yen and existing cash on hand. Astellas expects to repay this debt within the next five to seven years. The completion of the Acquisition is not subject to a financing condition. Astellas does not anticipate making any change in its dividend policy following the Acquisition.

    The closing of the proposed Acquisition is subject to approval by Iveric Bio's stockholders and other customary closing conditions, including receipt of required regulatory approvals. The companies expect to complete the Acquisition in the second quarter of Astellas' fiscal year 2023 (third calendar quarter of 2023). A copy of the merger agreement regarding the proposed Acquisition will be filed with the U.S. Securities and Exchange Commission ("SEC") and will be publicly available on the SEC's website at (http://www.sec.gov).

    2.  Overview of Iveric Bio

    1 Company

    IVERIC bio, Inc.

    2 Address

    8 Sylvan Way Parsippany, NJ 07054, US

    3 Representative's Title and Name

    CEO, Glenn P. Sblendorio

    4 Business Description

    R&D of pharmaceuticals

    5 Stated Capital

    US$ 137 thousand (as of December 31, 2022)

    6 Consolidated Stockholders' equity

    US$ 534,657 thousand (as of December 31, 2022)

    7 Year of Establishment

    2007

    8 Number of Shares Outstanding

      137,616,082 (as of April 27, 2023)

    9 Major shareholders

       and ownership ratio

       (*)

    Vanguard Group, Inc.: 7.4%

    BlackRock, Inc.: 7.1%

    Deep Track Capital, LP: 5.7%

    10 Relationship between Astellas and Iveric Bio



    Capital Relationship:

    There is no capital relationship between Astellas

    and Iveric Bio required to be disclosed.

    Personal Relationship:

    There is no personal relationship between Astellas

    and Iveric Bio required to be disclosed.

    Business Relationship:

    There is no business relationship between Astellas and Iveric Bio required to be disclosed.

    Status of

    A Related Party

       Iveric Bio is not an affiliated party of Astellas.

    11 Iveric Bio's consolidated operating results and consolidated financial position for the past three years(**)

    Accounting Period

    (in thousands except per share data)

    Fiscal year

    ended

    December,

    2020

    Fiscal year

    ended

    December,

    2021

    Fiscal year

    ended

    December,

    2022

    Total Equity

    191,563

    360,528

    534,657

    Total Assets

    216,754

    389,358

    666,823

    Equity per share (US $)

    2.58

    3.54

    4.42

    Revenue (***)

    -

    -

    -

    Operating Loss

    (88,736)

    (114,757)

    (189,906)

    Loss before taxes

    (88,242)

    (114,522)

    (185,211)

    Net Loss



    (84,547)

    (114,522)

    (185,211)

    Net Loss per share

    (US $)

    (1.14)

    (1.12)

    (1.53)

    Dividend per share

    (US $)

    -

    -

    -













    * Includes holdings of its subsidiaries and affiliates; based on information from Iveric Bio's definitive proxy statement filed on April 5, 2023, with the SEC in connection with Iveric Bio's planned annual stockholder meeting for 2023

    ** Excerpt from Iveric Bio's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed by Iveric Bio with the SEC on March 1, 2023

    *** There were no sales since these were before the product launch

    3.  Number of Iveric Bio shares to be acquired by Astellas, acquisition price, and status of shareholdings before and after the Acquisition

    1 Number of Iveric Bio shares held by Astellas before the Acquisition

    0 (as of April 27, 2023)

    (Number of voting rights: 0)

    (Ownership ratio of voting rights: 0%)

    2 Number of Iveric Bio Shares Outstanding as of April 27, 2023

    137,616,082 shares

    3 Acquisition amount (****)

    US$40 per share (approximately US$5.9 billion in the aggregate)

    4 Percentage of Iveric Bio shares to be held after the Acquisition

    100%

    (Number of voting rights: 100%)

     (Ownership ratio of voting rights: 100%)

    **** Acquisition amount includes the full amount required to purchase all outstanding options and restricted stock units

     

         4.  Schedule

    1 Date of Definitive Agreement



    April 29, 2023 (Japan time)



    2 Estimated Date of stockholder meeting to be held by Iveric Bio

    second quarter of Astellas' fiscal year 2023

    (third calendar quarter of 2023)

     

    3 Estimated Date of Closing (*****)

    second quarter of Astellas' fiscal year 2023

    (third calendar quarter of 2023

    ***** Subject to applicable regulatory approvals

    5.  Financial Impact of the Acquisition

    The impact of the consummation of the Acquisition on Astellas' financial results is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending March 31, 2024, that were announced on April 27, 2023. Astellas is still reviewing the impact and will promptly announce any events that are to be publicly reported.

    6.  Financial and Legal Advisors

    J.P. Morgan Securities LLC, acting through its affiliate JPMorgan Securities Japan Co., Ltd., is acting as exclusive financial advisor to Astellas and Jones Day is acting as Astellas' legal counsel.  BofA Securities, Inc. and Centerview Partners LLC are serving as Iveric Bio's exclusive financial advisors and Skadden, Arps, Slate, Meagher & Flom LLP is serving as Iveric Bio's legal counsel, with Wilmer Cutler Pickering Hale and Dorr LLP advising on general corporate and licensing matters.

    *1:  The FDA's breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. FDA will review the full data submitted to support approval of drugs designated as breakthrough therapies to determine whether the drugs are safe and effective for their intended use before they are approved for marketing.

    About Astellas' Primary Focus "Blindness & Regeneration"

    The Primary Focus' mission is to identify, develop and deliver next generation treatments to restore sight for patients with retinal diseases. Astellas is passionate about R&D to increase productivity and creativity and deliver innovative treatments to patients as quickly as possible by combining optimal internal and external capabilities. For more information, please visit our website at https://www.astellas.com/en/innovation/primary-focus-blindness-regeneration.

    About Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    Age-related macular degeneration (AMD) is the major cause of moderate and severe loss of central vision in aging adults, affecting both eyes in the majority of patients. The macula is a small area in the central portion of the retina responsible for central vision. As AMD progresses, the loss of retinal cells and the underlying blood vessels in the macula results in marked thinning and/or atrophy of retinal tissue. Geographic atrophy secondary to AMD, leads to irreversible loss of vision in patients and has a high unmet medical need. It is estimated that approximately 1.6 million people in the U.S. have GA in at least one eye1.

    About Avacincaptad Pegol(ACP)

    Avacincaptad pegol (ACP) is an investigational drug that is currently under evaluation for safety and efficacy by the U.S. FDA. ACP is a novel complement C5 protein inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a critical role in the development and growth of scarring and vision loss associated with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). By targeting C5, ACP has the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of GA.

    About GATHER Clinical Trials

    ACP met its primary endpoint in the completed GATHER1 clinical trial and the ongoing GATHER2 clinical trial both of which are randomized, double-masked, sham-controlled, multicenter Phase 3 clinical trials. These clinical trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of ACP in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either ACP 2 mg or sham monthly. There were 286 participants enrolled in GATHER1 and 448 participants enrolled in GATHER2. The primary efficacy endpoints in both pivotal studies were based on GA area measured by fundus autofluorescence at three time points: Baseline, Month 6, and Month 12. The mean rate of growth (slope) in GA area from baseline to month 12 using observed data was 35% in GATHER 1 and 18% in GATHER2. In GATHER1 and GATHER2 combined, the most frequently reported treatment emergent adverse events in the 2 mg recommended dose were related to injection procedure. The most common adverse reactions (≥ 5% and greater than sham) reported in patients who received avacincaptad pegol 2 mg were conjunctival hemorrhage (13%), increased IOP (9%), and CNV (7%). After 18 months of treatment in GATHER1 and 12 months of treatment in GATHER2, there were no events of serious intraocular inflammation, vasculitis, or endophthalmitis.

    About Astellas

    Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.

    About Iveric Bio

    Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients' lives by delivering high-quality, safe, and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

    Cautionary Notice Regarding Forward-Looking Statements

    All statements in this press release, other than statements of historical fact, are statements that could be deemed "forward-looking statements"  In some cases, forward-looking statements may be identified by terminology such as "believe," "may," "will," "should", "predict", "goal", "strategy", "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect," "seek" and similar expressions and variations thereof.  Iveric Bio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. Private Securities Litigation Reform Act of 1995.

    This press release contains "forward-looking statements" relating to, among other things, the proposed acquisition of Iveric Bio by Astellas and the objectives of such proposed acquisition, Astellas' and Iveric Bio's beliefs and expectations regarding the potential benefits sought to be achieved by Astellas' proposed acquisition of Iveric Bio, the potential effects of the proposed acquisition on both Astellas and Iveric Bio, the expected benefits and success of Iveric Bio's product candidates, the potential for and anticipated timing for approval of ACP, the anticipated financing of the proposed acquisition, and the anticipated timing of completion of the proposed acquisition, each of which involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

    Risks and uncertainties include, among other things, risks related to the ability of Iveric Bio and Astellas to complete the transactions contemplated by the merger agreement; the satisfaction or waiver of the conditions to closing the proposed acquisition set forth in the merger agreement (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by Iveric Bio stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the timing and nature of regulatory filings for Iveric Bio' product candidates, and the possibility of a termination of the merger agreement; the possibility that competing offers to acquire Iveric Bio may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that Iveric Bio's business and products will not be integrated with those of Astellas successfully; the effects of disruption from the transactions contemplated by the merger agreement on Iveric Bio's business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Astellas' or Iveric Bio's common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or Iveric Bio's business; risks related to the financing of the acquisition; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data is subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for Iveric Bio's pipeline products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety or other matters that could affect the availability or commercial potential of such products; expectations regarding personnel and human capital matters; and competitive developments.

    Moreover, Astellas and Iveric Bio operate in very competitive and rapidly changing environments, and new risks emerge from time to time. Astellas and Iveric Bio have based these forward-looking statements  on their current expectations and projections about future events and trends that they believe may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs of Astellas and Iveric Bio, but they cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions, the timing and results of biotechnology development and potential regulatory approval. The foregoing factors are not exhaustive. You should also carefully consider other risks and uncertainties that may affect the business of Iveric Bio, including those described in the "Forward-Looking Statements", "Summary of Principal Risk Factors", and "Risk Factors"  sections of Iveric Bio' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC, all of which are available on the SEC's website at www.sec.gov.  These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.  Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements and Astellas and Iveric Bio assume no obligation to, and do not intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by applicable law.

    Additional Information and Where to Find It

    In connection with the proposed acquisition, Iveric Bio will be filing documents with the SEC, including preliminary and definitive proxy statements relating to the proposed acquisition. This press release is not a substitute for the proxy statement or any other document which Iveric Bio may file with the SEC.  The definitive proxy statement will be mailed to Iveric Bio's stockholders in connection with the proposed acquisition. BEFORE MAKING ANY VOTING DECISION, IVERIC BIO'S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION. Any vote in respect of resolutions to be proposed at Iveric Bio's stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Iveric Bio's proxy statement. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the United States Securities and Exchange Commission ("SEC") at the SEC's web site at www.sec.gov, and all documents filed by Iveric Bio with the SEC are available to all stockholders of Iveric Bio free of charge at [https://investors.ivericbio.com/financial-information/sec-filings]

    Participants in the Solicitation

    Iveric Bio, and its directors, executive officers and other members of management and certain other people may be deemed to be participants in the solicitation of proxies in connection with the proposed acquisition. Information about Iveric Bio's directors and executive officers is included in the proxy statement for Iveric Bio's annual meeting of stockholders for 2023, filed with the SEC on April 5, 2023. Additional information regarding these persons and their interests in the merger will be included in the proxy statement relating to the proposed acquisition when it is filed with the SEC. These documents, when available, can be obtained free of charge from the sources indicated above.

    Important Additional Information

    This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of Iveric Bio common stock or any other securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

    Reference

    ¹ Klein, et al. JAMA Ophthalmology. 2011.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/astellas-enters-into-definitive-agreement-to-acquire-iveric-bio-301811623.html

    SOURCE Astellas Pharma Inc.

    Get the next $ISEE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISEE

    DatePrice TargetRatingAnalyst
    5/1/2023Buy → Neutral
    Guggenheim
    11/10/2022$30.00 → $20.00Buy → Hold
    Jefferies
    10/17/2022Sell → Neutral
    B. Riley Securities
    9/6/2022$12.00 → $8.00Neutral → Sell
    B. Riley Securities
    8/2/2022$20.00Buy
    UBS
    6/8/2022$30.00Buy
    Guggenheim
    6/8/2022$18.00Buy
    BofA Securities
    5/12/2022$12.00Neutral
    B. Riley Securities
    More analyst ratings

    $ISEE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IVERIC bio downgraded by Guggenheim

      Guggenheim downgraded IVERIC bio from Buy to Neutral

      5/1/23 7:21:51 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio downgraded by Jefferies with a new price target

      Jefferies downgraded IVERIC bio from Buy to Hold and set a new price target of $20.00 from $30.00 previously

      11/10/22 6:43:18 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio upgraded by B. Riley Securities

      B. Riley Securities upgraded IVERIC bio from Sell to Neutral

      10/17/22 1:19:22 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Astellas Completes Acquisition of Iveric Bio

      TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t

      7/11/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on July 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 124,860 restricted stock units for shares of the Company's common stock. The restric

      7/5/23 4:05:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 15,745 restricted stock units for shares of the Company's common stock. The restr

      6/2/23 4:52:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    SEC Filings

    See more

    $ISEE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $ISEE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ISEE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 15-12G filed by IVERIC bio Inc.

      15-12G - IVERIC bio, Inc. (0001410939) (Filer)

      7/21/23 8:30:11 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by IVERIC bio Inc.

      EFFECT - IVERIC bio, Inc. (0001410939) (Filer)

      7/18/23 12:15:15 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by IVERIC bio Inc.

      25-NSE - IVERIC bio, Inc. (0001410939) (Subject)

      7/11/23 10:24:16 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for IZERVAY issued to IVERIC BIO, INC.

      Submission status for IVERIC BIO, INC.'s drug IZERVAY (ORIG-1) with active ingredient AVACINCAPTAD PEGOL has changed to 'Approval' on 08/04/2023. Application Category: NDA, Application Number: 217225, Application Classification: Type 1 - New Molecular Entity

      8/9/23 8:37:19 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/24 8:49:05 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/23 2:33:06 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/23 1:10:29 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Blumenkranz Mark S.

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:02:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Carroll David Francis

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:01:28 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Miller Christine Ann

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:00:53 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Leadership Updates

    Live Leadership Updates

    See more
    • Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer

      – Highly-Recognized Operational Executive and Strategic Advisor to Biotechnology Companies with a Proven Track Record – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Tony Gibney to Executive Vice President and Chief Business and Strategy Officer, effective December 13, 2021. Mr. Gibney is an experienced biotechnology executive and former investment banker. Mr. Gibney brings over 25 years of experience dedicated to advising biotechnology companies in the U.S. and Europe on corporate matters such as business strategy, collaboration transactions, financings, and mergers and acquisitions. As a biotechnology executive, Mr. Gibney completed multiple strategic transactions, an

      12/13/21 5:08:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Appoints Christopher Simms as Chief Commercial Officer

      – Former U.S. Franchise Head of Ophthalmics at Novartis Brings a Proven Track Record in Major Retinal Product Launches – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he successfully managed commercial operations for the U.S. Ophthalmics Franchise, launching BEOUV® (brolucizumab injection) for wet age-related macular degeneration (AMD). Before Novartis, he served as marketing lead for the Genentech ophthalmology business which included creating a new brand positioning and launching a new campaign for Lucentis® (ranibizumab in

      7/19/21 7:30:00 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on January 4, 2021, the Company granted non-statutory stock options to purchase an aggregate of 28,000 shares of the Company’s common stock to two newly hired, non-executive employees. These grants were made pursuant to the Company’s 2019 Inducement Stock Incentive Plan, were approved by the Company’s compensation committee pursuant to a delegation by the Company’s board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The stock options h

      1/5/21 8:00:00 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Financials

    Live finance-specific insights

    See more
    • Astellas Completes Acquisition of Iveric Bio

      TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t

      7/11/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astellas Enters into Definitive Agreement to Acquire Iveric Bio

      -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement un

      4/30/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

      -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio"))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a w

      4/30/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care